Fang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fang Wang has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Yaxuan He
Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China
6 shared publicationsWenjun Yang
Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China
5 shared publicationsYu Cao
Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China
5 shared publications- Zhaohui Mo
Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China
4 shared publications - Junlin Wei
Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China
3 shared publications Yuxing Liu
The Endocrinology Department of the Third Xiangya Hospital, Central South University, Changsha, China
3 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Springer Nature in Scientific Reports
Central obesity indices and the risk of heart disease, type 2 diabetes mellitus, and stroke: findings from a Chinese prospective cohort
Obesity is a major risk factor for cardiometabolic disease, but the relative value of different anthropometric indices for risk remains uncertain. Body mass index (BMI) is widely used but does not reflect fat distribution, whereas central obesity measures may better capture visceral adiposity. However, their associations with major cardiometabolic diseases have not been comprehensively compared in Asian populations. Using data from a large prospective cohort of Chinese adults, we compared the associations of BMI, waist circumference (WC), waist-to-height ratio (WHtR), body roundness index (BRI), a body shape index (ABSI), and weight-adjusted waist index (WWI) with incident heart disease, type 2 diabetes mellitus (T2DM), and stroke. Machine learning–assisted effect estimates were derived using a doubly robust Double Machine Learning framework and were complemented by Cox proportional hazards models. Restricted cubic spline analyses were used to explore nonlinear exposure–response relationships. Sensitivity analyses were conducted to assess the robustness of the findings. Most indices were positively associated with the outcomes, although the strength and statistical significance of the associations varied by index, outcome, and adjustment model. Waist-based central obesity indices, particularly WC, WHtR, and BRI, generally showed larger estimated effects and stronger associations with incident T2DM and stroke than BMI, whereas BMI showed associations comparable to those of central obesity indices for heart disease. In the primary confounder-adjusted model, the highest quartiles of BRI, WC, and WHtR were associated with hazard ratios above 4.0 for T2DM, whereas the corresponding hazard ratios ranged from 1.79 to 2.74 for heart disease and stroke. Associations were generally attenuated after additional adjustment in the clinical pathway-adjusted sensitivity analyses, with weaker and less stable findings for ABSI and WWI. Machine learning–assisted effect estimation and conventional survival analyses suggested that waist-based central obesity indices were more consistently associated with incident T2DM and stroke than BMI. Among the evaluated indices, WC, WHtR, and BRI showed broadly comparable performance and may provide useful complementary information for cardiometabolic risk stratification in Asian populations.
- 16 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessCentral obesity indices and the risk of heart disease, type 2 diabetes mellitus, and stroke: findings from a Chinese prospective cohort
Obesity is a major risk factor for cardiometabolic disease, but the relative value of different anthropometric indices for risk remains uncertain. Body mass index (BMI) is widely used but does not reflect fat distribution, whereas central obesity measures may better capture visceral adiposity. However, their associations with major cardiometabolic diseases have not been comprehensively compared in Asian populations. Using data from a large prospective cohort of Chinese adults, we compared the associations of BMI, waist circumference (WC), waist-to-height ratio (WHtR), body roundness index (BRI), a body shape index (ABSI), and weight-adjusted waist index (WWI) with incident heart disease, type 2 diabetes mellitus (T2DM), and stroke. Machine learning–assisted effect estimates were derived using a doubly robust Double Machine Learning framework and were complemented by Cox proportional hazards models. Restricted cubic spline analyses were used to explore nonlinear exposure–response relationships. Sensitivity analyses were conducted to assess the robustness of the findings. Most indices were positively associated with the outcomes, although the strength and statistical significance of the associations varied by index, outcome, and adjustment model. Waist-based central obesity indices, particularly WC, WHtR, and BRI, generally showed larger estimated effects and stronger associations with incident T2DM and stroke than BMI, whereas BMI showed associations comparable to those of central obesity indices for heart disease. In the primary confounder-adjusted model, the highest quartiles of BRI, WC, and WHtR were associated with hazard ratios above 4.0 for T2DM, whereas the corresponding hazard ratios ranged from 1.79 to 2.74 for heart disease and stroke. Associations were generally attenuated after additional adjustment in the clinical pathway-adjusted sensitivity analyses, with weaker and less stable findings for ABSI and WWI. Machine learning–assisted effect estimation and conventional survival analyses suggested that waist-based central obesity indices were more consistently associated with incident T2DM and stroke than BMI. Among the evaluated indices, WC, WHtR, and BRI showed broadly comparable performance and may provide useful complementary information for cardiometabolic risk stratification in Asian populations.
- 2 April 2026
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (5) , 419-422
Mitochondrial transfer as a therapeutic target for peripheral neuropathy
- 2 April 2026
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 32 (5) , 419-422
Mitochondrial transfer as a therapeutic target for peripheral neuropathy
- Open Access
- 25 March 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (1)
Mitochondrial Proteotoxicity: A New Frontier in Type 2 Diabetes?
- 25 March 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (1)
Open AccessMitochondrial Proteotoxicity: A New Frontier in Type 2 Diabetes?
- Open Access
- 3 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a highly prevalent liver condition closely linked to obesity, insulin resistance, and metabolic syndrome. Early identification of MAFLD remains challenging in routine health examination settings remain challenging, especially in routine health examination settings where conventional indicators often fail to capture deeper metabolic disturbances. This study aimed to evaluate the predictive value of body composition parameters and develop and validate a non-invasive, machine learning-based classification model for MAFLD. A retrospective study was conducted using data from 23,348 adults who underwent health check-ups between 2017 and 2021 at a tertiary hospital in China. Body composition was assessed via bioelectrical impedance analysis, and MAFLD was diagnosed based on hepatic steatosis plus metabolic risk criteria. A total of 13 features, including body composition indicators and basic demographics, were initially considered. Feature selection was guided by multicollinearity diagnostics and model-based importance analysis. Eight machine learning models were constructed and evaluated using tenfold cross-validation. An independent external validation cohort of 3,357 participants from 2022 to 2023 was used to assess generalizability. Performance was evaluated using area under the receiver operating characteristic curve, accuracy, recall, F1 score, and calibration metrics. Among all models, tree-based algorithms including extreme gradient boosting, gradient boosting decision tree, and LightGBM achieved the highest discriminative performance, with internal validation area under the curve values exceeding 0.96 and external validation area under the curve values above 0.95. Visceral fat rating consistently emerged as the most important predictor, followed by waist circumference and body mass index. Logistic regression confirmed their independent associations with MAFLD after adjustment for key confounders. Stratified analyses revealed variable patterns across sex, age, and body mass index groups, with visceral fat remaining a robust predictor in all subgroups. Body composition analysis, particularly visceral fat estimation, demonstrates strong diagnostic discrimination for MAFLD using non-invasive measurements. Integrating these parameters with machine learning enables accurate identification, supporting scalable screening and aiding diagnostic assessment in routine health examination, clinical, and public health settings.
- 3 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a highly prevalent liver condition closely linked to obesity, insulin resistance, and metabolic syndrome. Early identification of MAFLD remains challenging in routine health examination settings remain challenging, especially in routine health examination settings where conventional indicators often fail to capture deeper metabolic disturbances. This study aimed to evaluate the predictive value of body composition parameters and develop and validate a non-invasive, machine learning-based classification model for MAFLD. A retrospective study was conducted using data from 23,348 adults who underwent health check-ups between 2017 and 2021 at a tertiary hospital in China. Body composition was assessed via bioelectrical impedance analysis, and MAFLD was diagnosed based on hepatic steatosis plus metabolic risk criteria. A total of 13 features, including body composition indicators and basic demographics, were initially considered. Feature selection was guided by multicollinearity diagnostics and model-based importance analysis. Eight machine learning models were constructed and evaluated using tenfold cross-validation. An independent external validation cohort of 3,357 participants from 2022 to 2023 was used to assess generalizability. Performance was evaluated using area under the receiver operating characteristic curve, accuracy, recall, F1 score, and calibration metrics. Among all models, tree-based algorithms including extreme gradient boosting, gradient boosting decision tree, and LightGBM achieved the highest discriminative performance, with internal validation area under the curve values exceeding 0.96 and external validation area under the curve values above 0.95. Visceral fat rating consistently emerged as the most important predictor, followed by waist circumference and body mass index. Logistic regression confirmed their independent associations with MAFLD after adjustment for key confounders. Stratified analyses revealed variable patterns across sex, age, and body mass index groups, with visceral fat remaining a robust predictor in all subgroups. Body composition analysis, particularly visceral fat estimation, demonstrates strong diagnostic discrimination for MAFLD using non-invasive measurements. Integrating these parameters with machine learning enables accurate identification, supporting scalable screening and aiding diagnostic assessment in routine health examination, clinical, and public health settings.
- 21 January 2026
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 37 (2) , 101-103
Reversing vascular aging by restoring macrophages
- 21 January 2026
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 37 (2) , 101-103
Reversing vascular aging by restoring macrophages
- Open Access
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging
Cardiovascular aging, characterized by endothelial dysfunction, arterial stiffening, and myocardial remodeling, is a major contributor to the development of age-related cardiovascular disease. Metformin, a first-line therapy for type 2 diabetes, has attracted interest as a promising geroprotective agent due to its ability to target several fundamental aging pathways. Mechanism: Beyond glucose-lowering effects, metformin may confer cardiovascular benefits through activation of AMP-activated protein kinase and inhibition of mitochondrial complex I. Preclinical work suggests these pathways enhance mitochondrial biogenesis, reduce oxidative stress, promote autophagy, and suppress chronic inflammation. Furthermore, metformin has been reported to modulate epigenetic clocks and support genomic stability, potentially mitigating several hallmarks of aging. Clinical Evidence: Although preclinical evidence is substantial, clinical findings remain heterogeneous. Observational studies and trials like UKPDS suggest cardiovascular benefits, whereas randomized controlled trials (RCTs) such as TAYSIDE, GIPS-III, REMOVAL and GOMET yielded inconsistent results for both clinical and surrogate cardiovascular endpoints. Result interpretations are often limited by relatively small sample sizes and short follow-up durations. Sex Differences and Limitations: Emerging evidence suggests sexual dimorphism in metformin responses, potentially influenced by hormonal status and pharmacokinetics. Additional challenges include the hormetic dose-response, the heterogeneity and frailty of older populations, and the absence of validated aging-specific cardiovascular endpoints. Metformin remains a promising candidate to mitigate cardiovascular aging. However, definitive conclusions regarding its efficacy in non-diabetic older adults will require large-scale, long-term RCTs incorporating aging-related biomarkers and stratification according to sex and metabolic status.
- 1 January 2026
- Published by Aging and Disease in Aging and disease
Open AccessMetformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging
Cardiovascular aging, characterized by endothelial dysfunction, arterial stiffening, and myocardial remodeling, is a major contributor to the development of age-related cardiovascular disease. Metformin, a first-line therapy for type 2 diabetes, has attracted interest as a promising geroprotective agent due to its ability to target several fundamental aging pathways. Mechanism: Beyond glucose-lowering effects, metformin may confer cardiovascular benefits through activation of AMP-activated protein kinase and inhibition of mitochondrial complex I. Preclinical work suggests these pathways enhance mitochondrial biogenesis, reduce oxidative stress, promote autophagy, and suppress chronic inflammation. Furthermore, metformin has been reported to modulate epigenetic clocks and support genomic stability, potentially mitigating several hallmarks of aging. Clinical Evidence: Although preclinical evidence is substantial, clinical findings remain heterogeneous. Observational studies and trials like UKPDS suggest cardiovascular benefits, whereas randomized controlled trials (RCTs) such as TAYSIDE, GIPS-III, REMOVAL and GOMET yielded inconsistent results for both clinical and surrogate cardiovascular endpoints. Result interpretations are often limited by relatively small sample sizes and short follow-up durations. Sex Differences and Limitations: Emerging evidence suggests sexual dimorphism in metformin responses, potentially influenced by hormonal status and pharmacokinetics. Additional challenges include the hormetic dose-response, the heterogeneity and frailty of older populations, and the absence of validated aging-specific cardiovascular endpoints. Metformin remains a promising candidate to mitigate cardiovascular aging. However, definitive conclusions regarding its efficacy in non-diabetic older adults will require large-scale, long-term RCTs incorporating aging-related biomarkers and stratification according to sex and metabolic status.
- Open Access
- 18 August 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-14
Predictive value and robustness of the stress hyperglycemia ratio combined with hypertension for stroke risk: evidence from the CHARLS cohort
Stroke remains a major cause of death and long-term disability worldwide, particularly in low- and middle-income countries. Early identification of individuals at high risk is essential for prevention. The stress hyperglycemia ratio (SHR), a novel indicator integrating acute and chronic glycemic states, has shown prognostic value in acute illness. However, its association with stroke risk in community populations and its potential interaction with hypertension remain unclear. This retrospective cohort study included 9682 stroke-free participants aged ≥ 45 years from the 2011 baseline of the China Health and Retirement Longitudinal Study (CHARLS), followed through 2020. SHR was calculated using fasting blood glucose and glycated hemoglobin. Participants were categorized by median SHR and hypertension status into four groups. Cox proportional hazards models were used to assess associations with incident stroke over a median follow-up of 8.43 years. Subgroup, stratified, and sensitivity analyses were performed. Predictive performance was evaluated using receiver operating characteristic (ROC) curve analysis. During 81,601 person-years of follow-up, 764 incident stroke cases were documented, with an overall incidence of 9.36 per 1000 person-years. Compared to the reference group (low SHR without hypertension), those with high SHR and hypertension had the highest stroke risk (hazard ratio: 2.94, 95% confidence interval: 2.38–3.64). SHR and hypertension were independently associated with stroke risk, and their combination demonstrated a dose-response relationship. Subgroup analyses confirmed consistent findings across sex and age strata. The combined SHR-hypertension model showed improved discriminative ability (area under the ROC curve: 0.653). Sensitivity analyses confirmed the robustness of the results. Elevated SHR is independently associated with an increased risk of stroke, and its predictive value is enhanced when combined with hypertension. SHR may serve as an integrated metabolic marker reflecting both acute stress and chronic risk burden. Incorporating SHR into stroke risk assessment tools may improve early identification and enable more targeted prevention strategies, particularly in hypertensive populations.
- 18 August 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-14
Open AccessPredictive value and robustness of the stress hyperglycemia ratio combined with hypertension for stroke risk: evidence from the CHARLS cohort
Stroke remains a major cause of death and long-term disability worldwide, particularly in low- and middle-income countries. Early identification of individuals at high risk is essential for prevention. The stress hyperglycemia ratio (SHR), a novel indicator integrating acute and chronic glycemic states, has shown prognostic value in acute illness. However, its association with stroke risk in community populations and its potential interaction with hypertension remain unclear. This retrospective cohort study included 9682 stroke-free participants aged ≥ 45 years from the 2011 baseline of the China Health and Retirement Longitudinal Study (CHARLS), followed through 2020. SHR was calculated using fasting blood glucose and glycated hemoglobin. Participants were categorized by median SHR and hypertension status into four groups. Cox proportional hazards models were used to assess associations with incident stroke over a median follow-up of 8.43 years. Subgroup, stratified, and sensitivity analyses were performed. Predictive performance was evaluated using receiver operating characteristic (ROC) curve analysis. During 81,601 person-years of follow-up, 764 incident stroke cases were documented, with an overall incidence of 9.36 per 1000 person-years. Compared to the reference group (low SHR without hypertension), those with high SHR and hypertension had the highest stroke risk (hazard ratio: 2.94, 95% confidence interval: 2.38–3.64). SHR and hypertension were independently associated with stroke risk, and their combination demonstrated a dose-response relationship. Subgroup analyses confirmed consistent findings across sex and age strata. The combined SHR-hypertension model showed improved discriminative ability (area under the ROC curve: 0.653). Sensitivity analyses confirmed the robustness of the results. Elevated SHR is independently associated with an increased risk of stroke, and its predictive value is enhanced when combined with hypertension. SHR may serve as an integrated metabolic marker reflecting both acute stress and chronic risk burden. Incorporating SHR into stroke risk assessment tools may improve early identification and enable more targeted prevention strategies, particularly in hypertensive populations.
- 5 August 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (4) , 1-20
UHRF1 in endothelial cells is essential for angiogenesis and associated with the activation of pro-angiogenic signaling pathways and expression of endothelial genes
Epigenetics is increasingly recognized as a crucial factor in angiogenesis. Ubiquitin-like with PHD and RING Finger Domains 1 (UHRF1) is an important epigenetic regulatory protein involved in regulating cellular life processes, developing many diseases. However, its potential role in regulating embryonic vascular development and postnatal angiogenesis is unclear. Our study found that endothelial cell-specific UHRF1 knockout mice showed obvious developmental disorders at the embryonic stage (E11.5-15.5), including impaired development of the individual embryo size and organs, sparse vascularity in the yolk sac, or even death. In the lower limb ischemia model, UHRF1 expression in ischemic muscle tissues of mice is proportionate to the regeneration of blood vessels. To confirm the specific inhibition of UHRF1, we transfected an adeno-associated virus serotype 9 which inserted a TIE-2 promoter and mediated the delivery of short hairpin RNA (AAV9-TIE-2-shUHRF1) into mouse vascular endothelial cells to knock down UHRF1 specifically. We observed that the knockdown of UHRF1 in endothelial cells results in poorer lower limb perfusion in mice. Mechanically, UHRF1 knockdown decreased the tube-forming capacity of ECFCs, whereas overexpression of UHRF1 by diabetic ECFCs where UHRF1 expression is typically downregulated significantly increased the tube-forming capacity of the cells. RNAseq and related bioinformatics analyses showed that differentially expressed genes (DEGs) were mainly involved in angiogenesis-related pathways. The results of qPCR and western blot showed that the protein and mRNA levels of angiogenesis-related factors (VEGF, PDGF, and ANGPT1), as well as vascular endothelial surface marker molecules (VEGFR2, CD31, and c-Kit), were down-regulated accordingly. Furthermore, ChIP experiments showed that UHRF1 was able to bind the promoters of VEGFR2 and CD31, affecting the levels of histone-methylated protein (H3K4me3 and H3K27me3) enriched in the promoter region. However, the expression of CD31 and VEGFR2 can be reversed separately after the transformation of different histone-methylated protein levels (H3K4me3 and H3K27me3). Taken together, UHRF1 may regulate angiogenic gene expression and vascular endothelial cell differentiation through epigenetic mechanisms and is essential for angiogenesis.
- 5 August 2025
- Published by Springer Nature in Angiogenesis
- Vol. 28 (4) , 1-20
UHRF1 in endothelial cells is essential for angiogenesis and associated with the activation of pro-angiogenic signaling pathways and expression of endothelial genes
Epigenetics is increasingly recognized as a crucial factor in angiogenesis. Ubiquitin-like with PHD and RING Finger Domains 1 (UHRF1) is an important epigenetic regulatory protein involved in regulating cellular life processes, developing many diseases. However, its potential role in regulating embryonic vascular development and postnatal angiogenesis is unclear. Our study found that endothelial cell-specific UHRF1 knockout mice showed obvious developmental disorders at the embryonic stage (E11.5-15.5), including impaired development of the individual embryo size and organs, sparse vascularity in the yolk sac, or even death. In the lower limb ischemia model, UHRF1 expression in ischemic muscle tissues of mice is proportionate to the regeneration of blood vessels. To confirm the specific inhibition of UHRF1, we transfected an adeno-associated virus serotype 9 which inserted a TIE-2 promoter and mediated the delivery of short hairpin RNA (AAV9-TIE-2-shUHRF1) into mouse vascular endothelial cells to knock down UHRF1 specifically. We observed that the knockdown of UHRF1 in endothelial cells results in poorer lower limb perfusion in mice. Mechanically, UHRF1 knockdown decreased the tube-forming capacity of ECFCs, whereas overexpression of UHRF1 by diabetic ECFCs where UHRF1 expression is typically downregulated significantly increased the tube-forming capacity of the cells. RNAseq and related bioinformatics analyses showed that differentially expressed genes (DEGs) were mainly involved in angiogenesis-related pathways. The results of qPCR and western blot showed that the protein and mRNA levels of angiogenesis-related factors (VEGF, PDGF, and ANGPT1), as well as vascular endothelial surface marker molecules (VEGFR2, CD31, and c-Kit), were down-regulated accordingly. Furthermore, ChIP experiments showed that UHRF1 was able to bind the promoters of VEGFR2 and CD31, affecting the levels of histone-methylated protein (H3K4me3 and H3K27me3) enriched in the promoter region. However, the expression of CD31 and VEGFR2 can be reversed separately after the transformation of different histone-methylated protein levels (H3K4me3 and H3K27me3). Taken together, UHRF1 may regulate angiogenic gene expression and vascular endothelial cell differentiation through epigenetic mechanisms and is essential for angiogenesis.
- Open Access
- 1 August 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-14
Machine learning with the body roundness index and associated indicators: a new approach to predicting metabolic syndrome
Metabolic syndrome (MetS) is strongly associated with increased cardiovascular morbidity and mortality. Traditional invasive diagnostic methods are costly, inconvenient, and unsuitable for large-scale screening. Developing a non-invasive, accurate prediction model is clinically significant for early MetS detection and prevention. To develop a non-invasive prediction model for MetS by integrating body roundness index (BRI), gender, age, height, and waist circumference with machine learning algorithms, and to validate its generalizability across different ethnic groups. We trained and validated machine learning models using a retrospective health examination dataset from Central South University (D1, n = 268,942) and externally validated them on a European cohort (D2, n = 60,799). Five non-invasive features—BRI, waist circumference, height, age, and gender—were used as predictors. MetS was diagnosed based on the IDF criteria. Ten machine learning algorithms were evaluated using 10-fold cross-validation. Model performance was assessed via accuracy, specificity, sensitivity, F1-score, precision, ROC AUC and Brier score. Additional analyses included threshold sensitivity testing (0.1–0.9) and ablation of central adiposity features to evaluate robustness and generalizability. In the D1, the prevalence of MetS was 18.26%. In the D2, the prevalence was 9.07%. Among all predictors, BRI demonstrated the strongest correlation with MetS (r = 0.585 in D1; r = 0.426 in D2; both P < 0.01). Compared with a rule-based baseline (F1 score = 0.50), all machine learning models achieved superior performance. At the default 0.5 threshold, XGBoost attained an AUC of 0.94, sensitivity of 0.96, and F1 score of 0.53 in D2. Further threshold adjustment improved XGBoost’s precision from 0.36 to 0.43, while maintaining high sensitivity (0.87). Model performance declined markedly when central adiposity features (BRI and WC) were removed, highlighting the critical predictive value of BRI. These findings support the utility of BRI-integrated ML approaches for scalable, non-invasive MetS screening. The combination of BRI and machine learning provides a non-invasive and effective method for predicting MetS and offers a promising strategy for its early prevention. Machine learning models demonstrate significant advantages over baseline rule-based models in terms of sensitivity and predictive performance.
- 1 August 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-14
Open AccessMachine learning with the body roundness index and associated indicators: a new approach to predicting metabolic syndrome
Metabolic syndrome (MetS) is strongly associated with increased cardiovascular morbidity and mortality. Traditional invasive diagnostic methods are costly, inconvenient, and unsuitable for large-scale screening. Developing a non-invasive, accurate prediction model is clinically significant for early MetS detection and prevention. To develop a non-invasive prediction model for MetS by integrating body roundness index (BRI), gender, age, height, and waist circumference with machine learning algorithms, and to validate its generalizability across different ethnic groups. We trained and validated machine learning models using a retrospective health examination dataset from Central South University (D1, n = 268,942) and externally validated them on a European cohort (D2, n = 60,799). Five non-invasive features—BRI, waist circumference, height, age, and gender—were used as predictors. MetS was diagnosed based on the IDF criteria. Ten machine learning algorithms were evaluated using 10-fold cross-validation. Model performance was assessed via accuracy, specificity, sensitivity, F1-score, precision, ROC AUC and Brier score. Additional analyses included threshold sensitivity testing (0.1–0.9) and ablation of central adiposity features to evaluate robustness and generalizability. In the D1, the prevalence of MetS was 18.26%. In the D2, the prevalence was 9.07%. Among all predictors, BRI demonstrated the strongest correlation with MetS (r = 0.585 in D1; r = 0.426 in D2; both P < 0.01). Compared with a rule-based baseline (F1 score = 0.50), all machine learning models achieved superior performance. At the default 0.5 threshold, XGBoost attained an AUC of 0.94, sensitivity of 0.96, and F1 score of 0.53 in D2. Further threshold adjustment improved XGBoost’s precision from 0.36 to 0.43, while maintaining high sensitivity (0.87). Model performance declined markedly when central adiposity features (BRI and WC) were removed, highlighting the critical predictive value of BRI. These findings support the utility of BRI-integrated ML approaches for scalable, non-invasive MetS screening. The combination of BRI and machine learning provides a non-invasive and effective method for predicting MetS and offers a promising strategy for its early prevention. Machine learning models demonstrate significant advantages over baseline rule-based models in terms of sensitivity and predictive performance.